BIOVIE

BioVie is pioneering an innovative therapeutic approach targeting ascites due to liver cirrhosis. Ascites, or the accumulation of fluid in the abdomen, is the most common complication of cirrhosis due to NASH (non-alcoholic steatohepatitis), alcoholic liver disease and/or hepatitis C. Ascites affects about 100,000 Americans and many times more worldwide, and contributes substantially to mortality. Our therapy BIV201 is based on a drug that is not yet available in the US but is approved in about... 50 countries to treat related complications of liver cirrhosis. The Company, formerly knows as NanoAntibiotics, Inc., recently acquired LAT Pharma LLC. This merger provided our lead development program, BIV201. Following a pre-investigational new drug meeting (“pre-IND”) with the FDA in early 2016, the Company is now assembling its IND package, and may commence a US clinical trial as early as 2017.More